Upstream Bio News and Activities

Upstream Bio is one of the...

• Russell 3000;
• TOB Iconic 10,000.

View the org chart displaying its 29 main executives

Most searched biographies at Upstream Bio

• Rand Sutherland, Chief Executive Officer and Director
• Marcella Ruddy, Director
• Daniella Beckman, Director

Popular executive movements at Upstream Bio

• Bryan Johnson has joined the company as Senior Director, Analytical  (posted on November 4 2025).

Create your alert
to follow the executive moves at Upstream Bio.

Upstream Bio has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Upstream Bio

• Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference — Mon, 05/18/2026 - 11:30
• Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights — Wed, 05/13/2026 - 07:01
• Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference — Fri, 04/17/2026 - 07:00
• Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results — Thu, 03/26/2026 - 07:00
• Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting — Sun, 03/01/2026 - 09:45
• Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 — Thu, 02/26/2026 - 07:00
• Upstream Bio to Participate in Upcoming March Investor Conferences — Wed, 02/25/2026 - 07:00
• Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma — Tue, 02/10/2026 - 18:00
• Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma — Wed, 02/11/2026 - 06:00
• Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference — Mon, 01/05/2026 - 07:00
• View more press releases Close

Social media about Upstream Bio

• Upstream Bio on Wikipedia, Google News & Yahoo Finance
• Upstream Bio on LinkedIn, X (Twitter) & YouTube